740 related articles for article (PubMed ID: 16285069)
1. Aripiprazole: new drug. Just another neuroleptic.
Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
[TBL] [Abstract][Full Text] [Related]
2. Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
Prescrire Int; 2007 Apr; 16(88):59-62. PubMed ID: 17458045
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
5. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
[TBL] [Abstract][Full Text] [Related]
7. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.
Klemp M; Tvete IF; Skomedal T; Gaasemyr J; Natvig B; Aursnes I
J Clin Psychopharmacol; 2011 Dec; 31(6):698-704. PubMed ID: 22020356
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
Charpeaud T; Samalin L; Llorca PM
Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole: a review of its pharmacology and clinical use.
Taylor DM
Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
[TBL] [Abstract][Full Text] [Related]
15. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Kane JM; Meltzer HY; Carson WH; McQuade RD; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
[TBL] [Abstract][Full Text] [Related]
18. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
[TBL] [Abstract][Full Text] [Related]
19. [Present data and treatment schedule of aripiprazole in the treatment of schizophrenia].
Limosin F; Azorin JM; Krebs MO; Millet B; Glikman J; Camus V; Crocq MA; Costentin J; Daléry J
Encephale; 2008 Jan; 34(1):82-92. PubMed ID: 18514155
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.
Prescrire Int; 2005 Aug; 14(78):140-2. PubMed ID: 16106596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
